Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Neurology
    November 2025
  1. DIMAURO KA, Manohar N, Aboseif A, Shah C, et al
    Leucine Zipper 4 Autoantibody-Associated Myeloneuropathy With Multiple Cranial Neuropathies and Longitudinally Extensive Tractopathy.
    Neurology. 2025;105:e214384.
    >> Share

  2. VILASECA A, Dalmau JO, Benarroch E
    What Are the Proposed Mechanisms Contributing to the Manifestations of Anti-NMDAR Encephalitis?
    Neurology. 2025;105:e214232.
    >> Share

  3. TASHIRO T, Ogata H, Fukami Y, Maimaitijiang G, et al
    Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.
    Neurology. 2025;105:e214143.
    >> Share

  4. KOZIK V, Dreiling M, Muller D, Tiedge O, et al
    Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study.
    Neurology. 2025;105:e214217.
    >> Share

  5. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    >> Share

  6. VOROBYEV A, Buciuc M, Perez Giraldo GS, Grewal P, et al
    Clinical Reasoning: A 56-Year-Old Woman With Right-Sided Weakness and Recurrent MRI Lesions.
    Neurology. 2025;105:e214293.
    >> Share

  7. PIERRET C, Leray E
    Author Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210260.
    >> Share

  8. GANESH A, Galetta SL
    Editors' Note: Understanding Cancer Risk Among Patients With Multiple Sclerosis.
    Neurology. 2025;105:e214342.
    >> Share

  9. SEJVAR JJ
    Guillain-Barre Syndrome: Grasping the "Rarity" of Outbreaks.
    Neurology. 2025;105:e214268.
    >> Share

  10. SONG Y, Wang L, Xuan Z
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210222.
    >> Share

  11. FENG Q
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210223.
    >> Share

    October 2025
  12. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2025;105:e213977.
    >> Share

  13. O'NEILL KA, Charvet L, Waltz M, George A, et al
    Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
    Neurology. 2025;105:e214142.
    >> Share

  14. OLIVIERI E, Muller J, Toosy AT
    Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
    Neurology. 2025;105:e214206.
    >> Share

  15. PORTACCIO E, Amato MP
    Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;105:e214244.
    >> Share

  16. LINDROOS JLV, Bjork MH, Cohen JM, Danielsson KC, et al
    Obstetric and Neonatal Outcomes in Patients With Maternal Myasthenia Gravis: A Nationwide Cohort Study.
    Neurology. 2025;105:e214139.
    >> Share

  17. SAHI N, Ciccarelli O, Houlden H, Chard DT, et al
    Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.
    Neurology. 2025;105:e214141.
    >> Share

  18. KRENN M, Wagner M, Schuller H, Pugna I, et al
    Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2025;105:e214177.
    >> Share

  19. SERRAO C, Rodrigues R, Guerreiro CL, Oliveira J, et al
    Pearls & Oy-sters: Adult-Onset Coats Plus: A Case of Leukoencephalopathy With Calcifications, a Tumefactive Brain Lesion, and a Presumed Autoimmune Disease.
    Neurology. 2025;105:e214124.
    >> Share

  20. NAUTIYAL K, Roy Chowdhury S, Meena R, Reddy N, et al
    Child Neurology: Parainfectious Anti-NMDAR Encephalitis With Anti-MOG and Anti-AQP4 Seropositivity in an Infant.
    Neurology. 2025;105:e214125.
    >> Share

  21. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
    Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis.
    Neurology. 2025;105:e214069.
    >> Share

  22. OVED K, Denkberg G, Pinzur L, Chroni E, et al
    Subunit-Specific Immunodominance in Clinically Distinct Populations With AChR+ Myasthenia Gravis: A Multiparametric Cross-Sectional Analysis.
    Neurology. 2025;105:e214150.
    >> Share

    September 2025
  23. THAKOLWIBOON S, Redenbaugh V, Chen B, Hewitt S, et al
    Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;105:e213903.
    >> Share

  24. CORTESE R, Sforazzini F, Gentile G, de Mauro A, et al
    Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease.
    Neurology. 2025;105:e214075.
    >> Share

  25. RENNER B, Verter ED, Absinta M, Daboul L, et al
    Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
    Neurology. 2025;105:e213912.
    >> Share

  26. CHARD DT
    Diagnosing Multiple Sclerosis: An Imperfect but Evolving Process.
    Neurology. 2025;105:e214057.
    >> Share

  27. MAREFI A, Grasso EA, Canna SW, Behrens EM, et al
    Clinical Reasoning: A 9-Year-Old Girl With CNS Immune Dysregulation.
    Neurology. 2025;105:e213999.
    >> Share

    August 2025
  28. HACOHEN Y, Ciccarelli O, Kunchok AC
    Diagnostic Criteria for Autoimmune Encephalitis in Children: Challenges and Need for Clinical Expertise.
    Neurology. 2025;105:e213946.
    >> Share

  29. SIEGLER JE, Galetta SL
    Editors' Note: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e213926.
    >> Share

  30. MENON D, Bril V, Barnett-Tapia C
    Author Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e210073.
    >> Share

  31. XU L, Zhou B, Xu Y
    Reader Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e210041.
    >> Share

  32. GAVOILLE A, Leray E, Marignier R, Rollot F, et al
    Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
    Neurology. 2025;105:e213907.
    >> Share

  33. BSTEH G, Hegen H
    Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple Sclerosis.
    Neurology. 2025;105:e214073.
    >> Share

  34. AL-ARAJI S, Moccia M, Jha A, Zhang L, et al
    Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;105:e213967.
    >> Share

  35. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;105:e213909.
    >> Share

  36. CORTESE M, Peng X, Edan G, Freedman MS, et al
    Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
    Neurology. 2025;105:e213905.
    >> Share

  37. ROBIN C, Rollot F, Lefort M, Casey R, et al
    Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
    Neurology. 2025;105:e213744.
    >> Share

  38. BOURDETTE D, Wooliscroft L
    Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?
    Neurology. 2025;105:e213971.
    >> Share

  39. CABRAL A, Lopes da Mota C, Rodrigues Casanova S, Martins de Campos A, et al
    Pearls & Oy-Sters: Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome.
    Neurology. 2025;105:e213848.
    >> Share

    July 2025
  40. WU L, Jiang W, Du R, Liu Y, et al
    Clinical Reasoning: Acute and Progressive Cognitive Decline in a 38-Year-Old Man.
    Neurology. 2025;105:e213871.
    >> Share

  41. PETERSSON M, Jons D, Feresiadou A, Ilinca A, et al
    Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.
    Neurology. 2025;105:e213771.
    >> Share

  42. ZHOU J, Nilius S, Pilipczuk O, Scowcroft A, et al
    Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
    Neurology. 2025;105:e213736.
    >> Share

  43. JIA A, Price TR, Rosner J, Broderick C, et al
    Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e213663.
    >> Share

    June 2025
  44. GOYNE C, Fair AE, Yilmaz D, Race J, et al
    Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;104:e213673.
    >> Share

  45. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Mortality in Myasthenia Gravis in Denmark From 1985 to 2020: A Population-Based Cohort Study.
    Neurology. 2025;104:e213745.
    >> Share

  46. YEH EA
    Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
    Neurology. 2025;104:e213840.
    >> Share

  47. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;104:e213650.
    >> Share

    May 2025
  48. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    >> Share

  49. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    >> Share

  50. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    >> Share

  51. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    >> Share

  52. DINOTO A, Cacciaguerra L, Vorasoot N, Redenbaugh V, et al
    Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;104:e213557.
    >> Share

  53. VU AP, Kapadia RK, Roberts JI
    Pearls & Oy-sters: Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Encephalomyelitis With Leptomeningeal Enhancement.
    Neurology. 2025;104:e213662.
    >> Share

  54. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
    Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
    Neurology. 2025;104:e213587.
    >> Share

  55. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
    Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
    Neurology. 2025;104:e213585.
    >> Share

  56. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    >> Share

  57. ZARA P, Chessa P, Deiana GA, Morette AM, et al
    Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice.
    Neurology. 2025;104:e213498.
    >> Share

  58. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    >> Share

    April 2025
  59. ZELIKOVICH AS, Zamorska B, Michaelson NM
    Patient Perspectives: Patient as Teacher: The Impact of Listening to a Patient With Stiff-Person Syndrome on Her Disease Course.
    Neurology. 2025;104:e213433.
    >> Share

  60. NAKAJIMA A, Hokari M, Yanagimura F, Saji E, et al
    Long-Term Clinical Landscapes of Spinal Hypertrophic Pachymeningitis With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Neurology. 2025;104:e213420.
    >> Share

  61. AL-SALAHAT A, Abdul Jabbar AB, Sharma R, Chen YT, et al
    Demographic and Geographic Trends in Myasthenia Gravis-Related Mortality in the United States, 1999-2022.
    Neurology. 2025;104:e213505.
    >> Share

  62. ABBOUD H, Clardy SL, Dubey D, Wickel J, et al
    The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and Opportunities.
    Neurology. 2025;104:e213487.
    >> Share

  63. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
    Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
    Neurology. 2025;104:e210274.
    >> Share

  64. GANESH A, Galetta SL
    Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
    Neurology. 2025;104:e213407.
    >> Share

  65. VIDAL-JORDANA A, Ontaneda D
    To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
    Neurology. 2025;104:e213416.
    >> Share

  66. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
    Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
    Neurology. 2025;104:e210259.
    >> Share

  67. MAVRIDIS A, Viktorisson A, Eliasson B, von Euler M, et al
    Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes: A Nationwide Cohort Study in Sweden.
    Neurology. 2025;104:e213480.
    >> Share

  68. MCAREE M, Frontera JA
    Clinical Reasoning: A 56-Year-Old Woman With New-Onset Hoarseness and Dysphagia.
    Neurology. 2025;104:e213363.
    >> Share

    March 2025
  69. GOH WGW, Ng IKS, Tan MKX, Fong CYK, et al
    Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.
    Neurology. 2025;104:e213434.
    >> Share

  70. MAILLART E, Dubessy AL, Shor N, Piljan M, et al
    Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e213399.
    >> Share

  71. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
    The Burden of Multiple Sclerosis in Mexico.
    Neurology. 2025;104:e213343.
    >> Share

    February 2025
  72. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
    Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
    Neurology. 2025;104:e213349.
    >> Share

  73. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
    Neurology. 2025;104:e210170.
    >> Share

  74. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
    Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
    Neurology. 2025;104:e213330.
    >> Share

  75. ROSS LA
    Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
    Neurology. 2025;104:e213366.
    >> Share

  76. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
    Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
    Neurology. 2025;104:e210142.
    >> Share

  77. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
    Age-Related Disability Outcomes After a First Demyelinating Event.
    Neurology. 2025;104:e210305.
    >> Share

  78. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
    Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
    Neurology. 2025;104:e210213.
    >> Share

  79. ROCCA MA, Preziosa P, Filippi M
    Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
    Neurology. 2025;104:e213396.
    >> Share

  80. BRENTON JN
    Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
    Neurology. 2025;104:e213321.
    >> Share

  81. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
    Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
    Neurology. 2025;104:e210251.
    >> Share

  82. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
    Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
    Neurology. 2025;104:e210281.
    >> Share

  83. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
    Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
    Neurology. 2025;104:e213332.
    >> Share


  84. Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis.
    Neurology. 2025;104:e210299.
    >> Share


  85. Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2025;104:e210298.
    >> Share

    January 2025
  86. TSAI CC, Chen J, Pikula A, Johnson EL, et al
    Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
    Neurology. 2025;104:e210289.
    >> Share

  87. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
    Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
    Neurology. 2025;104:e210228.
    >> Share

  88. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
    Neurology. 2025;104:e210149.
    >> Share

  89. CARVALHO IV, Gomes F, Almendra L, Geraldo A, et al
    Reversible Unilateral Tongue Border Atrophy Associated With Anti-Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.
    Neurology. 2025;104:e210288.
    >> Share

  90. CAGOL A, Montobbio N
    Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
    Neurology. 2025;104:e210272.
    >> Share

  91. CRUCIANI A, Toosy AT
    Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
    Neurology. 2025;104:e210296.
    >> Share

  92. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
    Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;104:e210153.
    >> Share

  93. WONG SH, Abuzaitoun R, Cornblath WT, Eggenberger ER, et al
    Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
    Neurology. 2025;104:e210150.
    >> Share

  94. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
    Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
    Neurology. 2025;104:e210136.
    >> Share

  95. CHEN B, Francis A, Cooper SA, Dobson R, et al
    Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e210137.
    >> Share

  96. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021: A Nationwide Population-Based Study.
    Neurology. 2025;104:e210139.
    >> Share

    December 2024
  97. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
    Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
    Neurology. 2024;103:e210080.
    >> Share

  98. BRENNER J, Ruhe CJ, Kulderij I, Bastiaansen AEM, et al
    Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.
    Neurology. 2024;103:e210109.
    >> Share

  99. SIRIRATNAM P, Huda S, Van Der Walt A, Sanfilippo PG, et al
    Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
    Neurology. 2024;103:e209940.
    >> Share

  100. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
    Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
    Neurology. 2024;103:e210140.
    >> Share

  101. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
    Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
    Neurology. 2024;103:e210049.
    >> Share

  102. CRANE PD, Sillau S, Dreher R, Fix R, et al
    Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System.
    Neurology. 2024;103:e210078.
    >> Share

  103. KLEIN CJ, Triplett JD, Murray DL, Gorsh AP, et al
    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.
    Neurology. 2024;103:e210000.
    >> Share

  104. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
    Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
    Neurology. 2024;103:e210003.
    >> Share

  105. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
    Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
    Neurology. 2024;103:e209991.
    >> Share

    November 2024
  106. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
    Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
    Neurology. 2024;103:e210004.
    >> Share

  107. WATANABE M, Isobe N, Niino M, Nakashima I, et al
    Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
    Neurology. 2024;103:e209992.
    >> Share

  108. SANTILLI AR, Ni O, Milone M, Selcen D, et al
    Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.
    Neurology. 2024;103:e210001.
    >> Share

  109. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    >> Share

  110. SHARMA R, Bellacicco NJ, Husar WG, Park JH, et al
    Pearls & Oy-sters: Breaking Bad CIDP: Recognition of Anti-NF155 Autoimmune Nodopathy in Refractory CIDP.
    Neurology. 2024;103:e209848.
    >> Share

  111. MICHAELSON NM, Klawiter EC, Singhal T
    Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
    Neurology. 2024;103:e210047.
    >> Share

  112. PONTILLO G, Prados F, Colman J, Kanber B, et al
    Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
    Neurology. 2024;103:e209976.
    >> Share

  113. BRUCKMAN D, Lee I, Schold JD, Claytor BR, et al
    Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019.
    Neurology. 2024;103:e210005.
    >> Share


  114. Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2024;103:e209968.
    >> Share

  115. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
    Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
    Neurology. 2024;103:e209952.
    >> Share

  116. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
    Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2024;103:e209885.
    >> Share

  117. GUPTA J, Choudhary R, Gupta A, Sharma P, et al
    Child Neurology: Acute Necrotizing Encephalopathy of Childhood Associated With Dengue: Good Neurologic Outcome Despite a Fulminant Presentation.
    Neurology. 2024;103:e209954.
    >> Share

  118. SIEGLER JE, Galetta SL
    Editors' Note: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209934.
    >> Share

  119. MOEHLMAN M
    Author Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209565.
    >> Share

  120. YANG Y, Li J, Tang Y
    Reader Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209545.
    >> Share

  121. MARIGNIER R, Kunchok A
    Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines.
    Neurology. 2024;103:e209970.
    >> Share

  122. RINGELSTEIN M, Asseyer S, Lindenblatt G, Fischer K, et al
    Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
    Neurology. 2024;103:e209888.
    >> Share

    October 2024
  123. SILVERMAN A, Sasaki M, Espindola Lima JE, Cheronis C, et al
    Child Neurology: Remarkable Recovery From Severe Acute Necrotizing Encephalopathy.
    Neurology. 2024;103:e209877.
    >> Share

  124. XU TT, Kaplan TM, Chen JJ
    Teaching NeuroImages: Cilioretinal Artery Occlusion Secondary to Antiphospholipid Syndrome.
    Neurology. 2024;103:e209901.
    >> Share

  125. SIEGLER JE 3RD, Galetta S
    Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209893.
    >> Share

  126. GROBOIS L, You M, Etienne M
    Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209508.
    >> Share

  127. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209515.
    >> Share

  128. HAY M, Rollot F, Casey R, Kerbrat A, et al
    Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
    Neurology. 2024;103:e209886.
    >> Share

  129. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
    Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
    Neurology. 2024;103:e209874.
    >> Share

  130. ROBERTS JI, Ng D, Kapadia R
    Pearls & Oy-sters: Tumour-Like Mass Lesion Secondary to Primary CNS Vasculitis.
    Neurology. 2024;103:e209819.
    >> Share


  131. Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
    Neurology. 2024;103:e209905.
    >> Share


  132. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;103:e209461.
    >> Share

  133. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
    Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
    Neurology. 2024;103:e209663.
    >> Share

  134. BLACKOWICZ M, James J, McNeil-Posey K, Schwartz T, et al
    Socioeconomic Factors Associated with >/=2-year Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States.
    Neurology. 2024;103.
    >> Share

  135. MANGIORIS G, Orozco E, Dubey D, Flanagan E, et al
    Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study.
    Neurology. 2024;103.
    >> Share

  136. VENKATARAMAN I, Ott A, Miske R, Scharf M, et al
    Performance Assessment of the New EUROLINE Neurologic Syndrome 15 Ag (IgG) for the Determination of Autoantibodies Associated with Neurological Disorders.
    Neurology. 2024;103.
    >> Share

    September 2024
  137. ROHM Z, Mobley B, Pawate S
    Teaching NeuroImage: Immunoglobulin G4-Related Hypophysitis.
    Neurology. 2024;103:e209809.
    >> Share

  138. ROVIRA A, Pareto D
    chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
    Neurology. 2024;103:e209735.
    >> Share

  139. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
    Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209604.
    >> Share

  140. BOURDETTE D
    Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
    Neurology. 2024;103:e209835.
    >> Share

  141. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
    Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
    Neurology. 2024;103:e209752.
    >> Share

  142. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
    Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209739.
    >> Share

  143. ZARA P, Solla P, Damato V, Sechi E, et al
    Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
    Neurology. 2024;103:e209756.
    >> Share

  144. SHIMIZU A, Noguchi-Shinohara M, Komatsu J, Ono K, et al
    Multifocal Intracranial Rosai-Dorfman Disease Mimicking Immunoglobulin G4-Related Pachymeningitis.
    Neurology. 2024;103:e209741.
    >> Share

  145. ABBOUD H, Farez MF
    The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
    Neurology. 2024;103:e209761.
    >> Share

  146. MOISSET X, Leray E, Chenaf C, Taithe F, et al
    Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
    Neurology. 2024;103:e209662.
    >> Share

    August 2024
  147. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
    Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
    Neurology. 2024;103:e209706.
    >> Share

  148. PASCUAL-GONI E, Caballero-Avila M, Querol L
    Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2024;103:e209725.
    >> Share

  149. MENON D, Alharbi M, Katzberg HD, Bril V, et al
    Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2024;103:e209722.
    >> Share

  150. TAGA A, Wali A, Eberhart CG, Green KE, et al
    Teaching NeuroImage: Giant Cell Arteritis With Optic Perineuritis.
    Neurology. 2024;103:e209707.
    >> Share

  151. WANG W
    Reader Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209441.
    >> Share

  152. WU J, Guo K, Liu J
    Author Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209463.
    >> Share

  153. LEWIS A, Galetta SL
    Editors' Note: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209736.
    >> Share


  154. Characterization Profiles of ANCA-associated Vasculitis With Neurological Manifestations (P7-14.007).
    Neurology. 2024;103:e209640.
    >> Share


  155. Artificial Intelligence-Based Ocular Motor Biomarkers for Myasthenia Gravis Diagnosis (P10-11.016).
    Neurology. 2024;103:e209639.
    >> Share

  156. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
    Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
    Neurology. 2024;103:e209598.
    >> Share

  157. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
    Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
    Neurology. 2024;103:e209677.
    >> Share

  158. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
    Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Neurology. 2024;103:e209610.
    >> Share

    July 2024
  159. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
    Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
    Neurology. 2024;103:e209574.
    >> Share

  160. GRANGEON L, Boulouis G, Capron J, Bala F, et al
    Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
    Neurology. 2024;103:e209548.
    >> Share

  161. GAVAZZI F, Vaia Y, Woidill S, Formanowski B, et al
    Nonverbal Cognitive Skills in Children With Aicardi Goutieres Syndrome.
    Neurology. 2024;103:e209541.
    >> Share

  162. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
    Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
    Neurology. 2024;103:e209444.
    >> Share

  163. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
    Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
    Neurology. 2024;103:e209543.
    >> Share

    June 2024
  164. KAMINSKI HJ, Kusner LL, Cutter GR, Le Panse R, et al
    Does Surgical Removal of the Thymus Have Deleterious Consequences?
    Neurology. 2024;102:e209482.
    >> Share

  165. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    >> Share

  166. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    >> Share

    May 2024
  167. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    >> Share

  168. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    >> Share

  169. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    >> Share

  170. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
    Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
    Neurology. 2024;102:e209395.
    >> Share

  171. LIAO J, Lu Y, Lu Y, Huang Y, et al
    Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
    Neurology. 2024;102:e209302.
    >> Share

  172. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    >> Share

  173. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    >> Share

  174. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
    Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
    Neurology. 2024;102:e209297.
    >> Share

    April 2024
  175. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
    Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
    Neurology. 2024;102:e209282.
    >> Share

  176. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
    Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
    Neurology. 2024;102:e209284.
    >> Share

  177. MOEHLMAN M, Kornbluh AB
    Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;102:e209259.
    >> Share


  178. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    >> Share

  179. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
    Pathologic Features of Anti-Ku Myositis.
    Neurology. 2024;102:e209268.
    >> Share

  180. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    >> Share

  181. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    >> Share

  182. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
    Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
    Neurology. 2024;102:e209245.
    >> Share

  183. THAKOLWIBOON S, Dubey D
    Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
    Neurology. 2024;102:e209213.
    >> Share

  184. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
    Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
    Neurology. 2024;102:e208101.
    >> Share

  185. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
    Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
    Neurology. 2024;102:e209257.
    >> Share

  186. AGYEI P, Chen M, Guo Y, Perez CA, et al
    Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
    Neurology. 2024;102:e209187.
    >> Share

  187. KUHLMANN G, Cloud B
    Characterization of the Earliest Adopters of Subcutaneous FcRn Blockers for gMG (P4-14.013).
    Neurology. 2024;102.
    >> Share

  188. YU Y, Kushlaf H
    Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
    Neurology. 2024;102.
    >> Share

  189. MASCANFRONI I, Manasson J, Pellerin A, Sanmarco L, et al
    Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases (P4-14.018).
    Neurology. 2024;102.
    >> Share

  190. WATANABE F, Fedorko J, Imitola J
    Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
    Neurology. 2024;102.
    >> Share

  191. OHRN S, Patel R, Ali A, Bauerschmidt A, et al
    Autonomic Dysfunction in Autoimmune Encephalitis: A Review of the Literature (P6-14.004).
    Neurology. 2024;102.
    >> Share

  192. ZAJNER C, Patil N, McInnis R, Van Uum S, et al
    Patterns of Extraocular Muscle Enlargement in Graves' Disease and Acromegaly (P7-10.005).
    Neurology. 2024;102.
    >> Share

  193. ROBERTS K, Cohn B, Sista SR
    Acetylcholine Binding Receptor Positivity from Passive Antibody Transfer in a Case of Progressive Muscular Atrophy (P11-11.009).
    Neurology. 2024;102.
    >> Share

  194. WEBER A, Rose J, DeWitt L
    NMOSD: Previously Seropositive Patient Presents with Seronegative Brainstem Attack (P11-14.017).
    Neurology. 2024;102.
    >> Share

  195. LOBAINA M, Valaparla VL, Shanina E
    Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
    Neurology. 2024;102.
    >> Share

  196. HABIB AA, Kaminski HJ, Grosskreutz J, Mantegazza R, et al
    Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001).
    Neurology. 2024;102.
    >> Share

  197. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
    A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
    Neurology. 2024;102.
    >> Share

  198. ROSE M, Hsu S, Balan A, Anderson A, et al
    Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
    Neurology. 2024;102.
    >> Share

  199. JAFFRY K, Karpenos S, Lin J, Matos J, et al
    Climate Change Associated with Declining Clinical Outcomes in Myasthenia Gravis for US States with the Greatest Temperature Increase (P4-14.004).
    Neurology. 2024;102.
    >> Share

  200. MAKAROVA A, Raju S, Ciotti J
    Parainfectious Hemorrhagic Longitudinally-extensive Transverse Myelitis Secondary to COVID-19 (P1-13.010).
    Neurology. 2024;102.
    >> Share

  201. WOODSON S, Gettings E, Guo CY, Klineova S, et al
    Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
    Neurology. 2024;102.
    >> Share

  202. VARNET M, Kayani S, Wang C
    Diagnostic Journey and Therapeutic Intervention of a Type-1 Interferonopathy in a Newborn (P6-8.002).
    Neurology. 2024;102.
    >> Share

  203. MIKAMI T, Levy M
    Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
    Neurology. 2024;102.
    >> Share

    March 2024
  204. YOUNG A, Johnston JL
    Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
    Neurology. 2024;102:e209260.
    >> Share

  205. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
    Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
    Neurology. 2024;102:e209130.
    >> Share

  206. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    >> Share

  207. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    >> Share

  208. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    >> Share

  209. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    >> Share


  210. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    >> Share

  211. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    >> Share

  212. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    >> Share

  213. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    >> Share

  214. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    >> Share

    February 2024
  215. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
    Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
    Neurology. 2024;102:e208019.
    >> Share

  216. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    >> Share

  217. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
    Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
    Neurology. 2024;102:e209153.
    >> Share

  218. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    >> Share

  219. WU J, Guo K, Liu J
    Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;102:e208064.
    >> Share

  220. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    >> Share

  221. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
    Patient With Rigidity and Fasciculations.
    Neurology. 2024;102:e208110.
    >> Share

  222. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    >> Share

    January 2024
  223. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    >> Share

  224. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
    Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
    Neurology. 2024;102:e207937.
    >> Share

  225. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    >> Share

  226. HABIB AA, Sacks N, Cool C, Durgapal S, et al
    Hospitalizations and Mortality From Myasthenia Gravis.
    Neurology. 2024;102:e207863.
    >> Share

  227. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    >> Share

  228. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    >> Share

  229. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    >> Share

  230. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    >> Share

  231. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    >> Share

  232. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
    Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2024;102:e207965.
    >> Share

  233. ALKABIE S, Gray MT, Lau JC, Barra L, et al
    Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
    Neurology. 2024;102:e208018.
    >> Share

    December 2023
  234. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    >> Share

  235. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
    Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
    Neurology. 2023;101:e2585-e2588.
    >> Share

  236. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    >> Share

    November 2023
  237. LI X, Stitt D, Lanzino G, Giannini C, et al
    Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2023;101:979-980.
    >> Share

    October 2023
  238. SRIVASTAVA I, Van Haren K
    Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
    >> Share

  239. BOURDETTE D, Silbermann E
    What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
    >> Share

  240. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
    Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
    >> Share

  241. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
    Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
    >> Share

  242. GUASP M, Dalmau J
    Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
    Neurology. 2023;101:656-660.
    >> Share

  243. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    >> Share

  244. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
    Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
    Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
    >> Share

    September 2023
  245. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    >> Share

  246. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    >> Share

  247. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    >> Share

  248. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    >> Share

  249. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    >> Share

  250. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    >> Share

    July 2023
  251. QUINN C, Moulton K, Farwell M, Le W, et al
    Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
    >> Share

  252. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    >> Share

  253. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    >> Share

    September 2022
  254. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    >> Share

    August 2022
  255. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
    Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016